Get the Stockscreener App
2.59
0.38%
-0.01
After Hours:
2.52
-0.07
-2.70%
Processa Pharmaceuticals Inc stock is traded at $2.59, with a volume of 61,096.
It is down -0.38% in the last 24 hours and up +39.25% over the past month.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.
See More
Previous Close:
$2.60
Open:
$2.69
24h Volume:
61,096
Relative Volume:
0.95
Market Cap:
$7.17M
Revenue:
-
Net Income/Loss:
$-14.11M
P/E Ratio:
-0.2416
EPS:
-10.7181
Net Cash Flow:
$-13.60M
1W Performance:
+16.67%
1M Performance:
+39.25%
6M Performance:
-18.81%
1Y Performance:
-57.33%
1-Day Range:
$2.5312
$2.7443
1-Week Range:
$2.15
$2.89
52-Week Range:
$1.6701
$14.24
Processa Pharmaceuticals Inc Stock (PCSA) Company Profile
Name
Processa Pharmaceuticals Inc
Sector
Industry
Phone
443-776-3133
Address
601 21ST STREET, SUITE 300, VERO BEACH
Compare PCSA vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCSA
Processa Pharmaceuticals Inc
|
2.59 | 7.20M | 0 | -14.11M | -13.60M | -10.72 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Processa Pharmaceuticals Inc Stock (PCSA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-25-24 | Initiated | H.C. Wainwright | Buy |
Processa Pharmaceuticals Inc Stock (PCSA) Latest News
Processa Pharmaceuticals Inc (PCSA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Processa Pharma Market Sentiment - Benzinga España
Processa Pharmaceuticals Inc (PCSA) Income Statement - TradingKey
PCSA|Processa Pharmaceuticals Inc|Price:2.600|Chg%:-0.270 - TradingKey
Processa Pharmaceuticals Inc (PCSA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Processa Pharmaceuticals Q4 2025 Earnings: EPS Miss Drives Stock Surge – Investor Focus Shifts to Pipeline - dars.gov.et
Processa Pharma (PCSA) Stock Analysis Report | Financials & Insights - Benzinga España
Insider Buying: Russell Skibsted Acquires Additional Shares of P - GuruFocus
Processa Pharmaceuticals CEO George Ng acquires $5,900 in stock - Investing.com
Processa Pharmaceuticals CEO George Ng acquires $5,900 in stock By Investing.com - Investing.com South Africa
Form 4 Processa Pharmaceuticals Inc For: 1 July By Investing.com - Investing.com Canada
Insider purchase: Processa (NASDAQ: PCSA) CAO adds 2,436 shares in open-market buy - Stock Titan
Processa (PCSA) strategy chief adds 2,106 shares in insider buy - Stock Titan
Processa Pharmaceuticals (PCSA) CEO adds 3,057 shares in open-market buy - Stock Titan
Processa Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Ng George K - Moomoo
CFO of Processa (NASDAQ: PCSA) adds 3,277 shares in open-market buy - Stock Titan
Processa Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer SKIBSTED RUSSELL - Moomoo
Processa Pharmaceuticals (PCSA) director buys 2,531 shares in open market - Stock Titan
Processa Pharmaceuticals, Inc. Financial Disclosures & SEC Filings - TradingView
Form 4 Processa Pharmaceuticals Inc For: 30 June By Investing.com - Investing.com Canada
Processa (NASDAQ: PCSA) director Yorke vests 203-share restricted stock award - Stock Titan
[Form 4] Processa Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Processa Pharmaceuticals (PCSA) director receives 203 shares from vesting - Stock Titan
Processa Pharmaceuticals (PCSA) director gets 203 shares from service award - Stock Titan
PCSA Q4 2025 Earnings: Wider-than-Expected Loss Highlights Clinical Stage ChallengesEarnings Turnaround - dars.gov.et
Enterprise value to EBIT forward of Processa Pharmaceuticals, Inc. – NASDAQ:PCSA - TradingView
Price to sales forward of Processa Pharmaceuticals, Inc. – NASDAQ:PCSA - TradingView
Price to book forward of Processa Pharmaceuticals, Inc. – NASDAQ:PCSA - TradingView
Price to earnings forward of Processa Pharmaceuticals, Inc. – NASDAQ:PCSA - TradingView
Enterprise value to revenue forward of Processa Pharmaceuticals, Inc. – NASDAQ:PCSA - TradingView
Processa Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:PCSA) - TradingView
PCSA | Processa Pharmaceuticals, Inc. Common Executive Compensation - Quiver Quantitative
Shareholders to vote on Processa (NASDAQ: PCSA) equity plan and pay - Stock Titan
Processa Pharmaceuticals | DEF 14A: Definitive information statements - Moomoo
Processa Pharmaceuticals Inc (PCSA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Processa Pharmaceuticals Inc (PCSA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Processa Pharmaceuticals Inc - TradingKey
Processa Pharmaceuticals Inc (PCSA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Processa Pharmaceuticals Inc (PCSA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Processa Pharmaceuticals Inc (PCSA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Processa Pharmaceuticals Inc (PCSA) Institutional Confidence - TradingKey
Processa Pharmaceuticals CFO Russell Skibsted buys $5,891 in stock By Investing.com - Investing.com UK
Processa Pharmaceuticals chief business officer Lin buys $4,064 stock By Investing.com - Investing.com India
Processa Pharmaceuticals CEO George Ng buys $5,472 in stock By Investing.com - Investing.com Australia
Processa Pharmaceuticals CFO Russell Skibsted buys $5,891 in stock - Investing.com
Processa Pharmaceuticals chief business officer Lin buys $4,064 stock - Investing.com UK
Processa Pharmaceuticals CEO George Ng buys $5,472 in stock - Investing.com UK
Processa Pharma president of R&D David Young buys $4,588 in stock - Investing.com Canada
Processa Pharma president of R&D David Young buys $4,588 in stock By Investing.com - Investing.com South Africa
Insider David Young adds 2,067 Processa (PCSA) shares at $2.22 - Stock Titan
Processa Pharmaceuticals (PCSA) CFO buys 2,654 shares in open market - Stock Titan
Processa Pharmaceuticals Inc Stock (PCSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):